Usefulness of novel tumour markers

Annals of Oncology

Volumn 10, Issue SUPPL. 4, 1999, Pages

  Rhodes, Jonathan M ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CA19.9; CAM17.1; DuPan2; Pancreas; SPan 1; Tumour markers

Indexed keywords

TUMOR MARKER;

CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; ECHOGRAPHY; HUMAN; PANCREAS CANCER; PRIORITY JOURNAL; SERODIAGNOSIS;

EID: 0032784841     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_4.S118     Document Type: Conference Paper

References (22)

1. Koprowski, H., Steplewski, Z., Mitchell, K. et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genetics 1979; 5: 957-72.
2. Thompson JN. Diagnosing cancer of the pancreas. BMJ 1990; 301: 1164.
3. Rhodes, J.M. and Ching, C.K. Serum diagnostic tests for pancreatic cancer. In Bailliere's Clinical Gastroenterology (ed. J. Neoptolemos), 1990 pp833-52. Bailliere Tindall, London.
4. JY Yiannakou, P Newland, F Calder et al. CAM17.1/WGA mucin assay for the serological diagnosis of pancreatic cancer: A prospective study in clinical practice. Lancet 1997; 349:389-92.
5. JM Rhodes, Y Yiannakou and CK Ching.Tumour markers in diagnosis of pancreatic cancer, in "The Pancreas: a Clinical Textbook" eds HG Beger, AL Warshaw, D Carr-Locke et al. 1998. Blackwell Scientific Publications, Oxford.
6. Magnani JL, Steplewski Z, Koprowski H et al. Identificiation of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of pateints as a mucin.. Cancer Res 1983;43:5489-92.
7. CK Ching, JM Rhodes.Identification and partial characterisation of a new pancreatic cancer related glycoprotein by SDS-PAGE and lectin blotting. Gastroenterology 1988; 95: 137-142.
8. Pineo GF, Brain MC, Galkes AS et al. Tumours, mucus production and hypercoagulability. Ann NY Acad Sci 1974;230:262-70.
9. Ogata S, Maimonis PJ, Itzkowta SH. Mucins bearing the cancer-asociated sialosyl-Tn antigen mediate inhibition of natural killer cell toxicity. Cancer Res 1992;52:4741-6.
10. Ching, C.K. and Rhodes, J.M., Purification and characterisation of the peanut-agglutinin binding pancreatic cancer-related serum glycoprotein. International Journal of Cancer, 1990;45: 1022-7.
11. Kawa, S., Kato, M., Oguchi, H. et al. Preparation of pancreatic cancer-associated mucin expressing CA19-9, CA50, Span-1, sialyl SSEA-1, and Dupan-2. Scandinavian Journal of Gastroenterology, 1991;26: 981-92.
12. Ferrara, C., Basso, D., Fabris, C. et al. Comparison of two newly identified tumor markers (CAR-3 and DU-PAN-2) with CA19-9 in patients with pancreatic cancer. Tumori, 1991;77: 56-60.
13. Kawa, S., Oguchi, H., Kobayashi, T. et al. Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. British Journal of Cancer, 1991;64: 899-902.
14. Satake, K., Chung, Y.S., Umeyama, K et al. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. Cancer, 1991;68: 149-52.
15. Steinberg, W. The clinical utility of the CA19-9 tumor- associated antigen. American Journal of Gastroenterology 1990;85: 350-5.
16. Chua E, Garvey C, Kingsnorth AN et al. A 49-year-old with a duodenal ulcer and a mass in the head of her pancreas. Lancet 1997;349:174 (case report).
17. Haglund C, Roberts P, Kuusela P et al. Evaluation of CA19-9 as a tumour marker in pancreatic cancer. Br J Cancer 1986;53: 197-202.
18. Steinberg WM, Gelfand R, Anderson KK et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Am J Gastroenterol 1986;90:343-9.
19. Beretta, E, Malesci, A., Zerbi, A. et al. Serum CA19-9 in the postsurgical follow-up of patients with pancreatic cancer. Cancer, 1987;60: 2428-31.
20. Bac, D.J., Kok, T.C., van der Gaast, A. et al. Evaluation of CA19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinoma. Journal of Cancer Research & Clinical Oncology, 1991;117: 263-5.
21. Glenn J, Steinberg WM, Kurtzman SH et al. Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988;6:462-8.
22. Moosa AR, Gadd M, Lavelle-Jones M. Surgical treatment of exocrine pancreatic cancer. In: Go VWL ed. The exocrine Pancreas: Biology, Pathology, and Diseases. New York: Raven, 1986, 713-25.